TP53 and retinoblastoma: The high MDM2 levels needed to drive MYCN expression exceed those needed to suppress p53-mediated apoptosis and thus abrogate the need for genomic inactivation of p53-mediated tumor surveillance signaling in retinoblastoma and neuroblastoma tumors (16, 17).